Is the marijuana industry on the verge of seeing more legal disputes surrounding patent infringement? One patent lawyer thinks it’s possible.

As the markets see the steady rise of the cannabis business, the possibility of an uptick in courtroom battles over patent use may be appearing soon enough.

In an interview with the Investing News Network (INN), Brian Shortell, a partner with law firm Ballard Spahr, said he is curious to see the development of legal disputes surrounding the enforcement of cannabis-related patents in state and federal courts given the status of the drug in the US.

Despite being legalized across several states for medical or even recreational uses, cannabis remains a scheduled drug at the US federal level. However, this past summer a Denver federal judge made history by allowing a cannabis patent lawsuit to move ahead into a jury trial.

According to a report from Marijuana Business Daily, the suit was filed by United Cannabis against Pure Hemp Collective — both Colorado-based firms — claiming infringement on a “cannabinoid-based medical product formula.”

Shortell told INN he expects to see disputes rise about the legality of enforcing patents for cannabis applications and cannabinoid-related technology.

“They are not finding them invalid based on the subject matter being marijuana,” Shortell said. Given the federal status of the drug, the expectation would have been for the suit to be dismissed.

In terms of the variance in patents related to the marijuana industry, the lawyer has predominantly seen patents connected to formulations, medical treatments and methods of processing.

“It’s basically patents related to taking the active ingredients and being able to use them in other products,” he explained.

Due to the many complications surrounding marijuana reform and policy, Shortell is curious about the impact of a potential winning patent lawsuit regarding cannabis, since the punishment for a court finding patent infringement is that lost profits are awarded.

“Will a court award money damages to a patent holder from the infringer for a substance for sale that is federally illegal?” he questioned.

While patents have different intentions and potential uses, Shortell reminded investors that a patent allows someone to go to court and stop someone from doing something.

“It’s called an exclusionary right or an exclusive right — we can exclude people from that activity or making that product … When one has a patent on a marijuana formulation they can go into court and stop people from making that marijuana formulation,” said Shortell. “The patent holder is doing nothing illegal by having the patent, the patent is to stop an infringer.”

Besides this case in Colorado, the lawyer has not seen any other notable patent-related cases with cannabis involved.

In a previous interview with INN, Dena Jalbert, founder and CEO of Align Business Advisory Services, said she expects to see an increase in the merger and acquisition deal-making space for cannabis based on intellectual property (IP).

“I think most of the deals that we’re going to see are going to be IP specific, because there’s only so much land,” Jalbert said.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less